A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXA inhibitors

Authors
Category Primary study
JournalBlood
Year 2013
This article has no abstract
Epistemonikos ID: 9177c4872f64a77d609e6c37515ced3e40f470bf
First added on: Feb 05, 2025